Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease

Carola Riva, Paola Minetto, Maria Chies, Elena Maio, Ylenia Azzanelli, Giada Zecchetti, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo

Blood (2024) 144 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2024-198174

Published: 2024

Journal Articles

High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction

Fabio Guolo, Carola Riva, Maria Chies, Chiara Vernarecci, Ylenia Azzanelli, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Michele Cea, Roberto Massimo Lemoli, Paola Minetto

Blood (2024) 144 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2024-198187

Published: 2024

Journal Articles

Excellent Outcome in NPM1- mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Paola Minetto, Carola Riva, Enrico Carminati, Ylenia Azzanelli, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Antonia Cagnetta, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo

Blood (2024) 144 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2024-198171

Published: 2024

Journal Articles

Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification

Carola Riva, Paola Minetto, Maria Chies, Chiara Vernarecci, Giada Zecchetti, Elena Maio, Ylenia Azzanelli, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Massimo Lemoli, Fabio Guolo

Blood (2024) 144 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2024-197943

Published: 2024

Journal Articles

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Chiara Vernarecci, Elena Maio, Mattia Montanari, Francesco Puglisi, Clara Nurra, Maurizio Miglino, Nicoletta Colombo, Enrico Carminati, Giada Zecchetti, Maria Chies, Beatrice Ferro, Massimo Zucchetti, Antonia Cagnetta, Michele Cea, Elisabetta Tedone, Roberto Massimo Lemoli, Fabio Guolo, Paola Minetto

Blood (2023) 142 (Supplement 1): 5879.

https://doi.org/10.1182/blood-2023-185082

Published: 2023

Journal Articles

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Blood (2023) 142 (Supplement 1): 2918.

https://doi.org/10.1182/blood-2023-189417

Published: 2023

Journal Articles

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

Blood (2023) 142 (Supplement 1): 2218.

https://doi.org/10.1182/blood-2023-189574

Published: 2023

Journal Articles

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Blood (2023) 142 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2023-188408

Published: 2023

Journal Articles

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

Giulia Giorgetti, Pamela Becherini, Elena Maroto-Martin, Daniela Fenoglio, Debora Soncini, Claudia Martinuzzi, Santina Bruzzone, Andrea Benzi, Aimable Nahimana, Chiara Rosa Maria Uras, Anaïs Schavgoulidze, Jessica Ng Fong, Roberto M. Lemoli, Nikhil C Munshi, Mariateresa Fulciniti, Michele Cea

Blood (2023) 142 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2023-189439

Published: 2023

Journal Articles

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Carola Riva, Paola Minetto, Enrico Carminati, Maria Chies, Chiara Vernarecci, Beatrice Ferro, Elena Maio, Giada Zecchetti, Michela Frello, Maurizio Miglino, Elisabetta Tedone, Nicoletta Colombo, Clara Nurra, Francesco Puglisi, Antonia Cagnetta, Michele Cea, Giuseppina Fugazza, Roberto Massimo Lemoli, Fabio Guolo

Blood (2023) 142 (Supplement 1): 6016.

https://doi.org/10.1182/blood-2023-186555

Published: 2023

Journal Articles

The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS

Debora Soncini, Pamela Becherini, Silvia Ravera, Claudia Martinuzzi, Alessio Nencioni, Santina Bruzzone, Francesco Piacente, Giulia Giorgetti, Francesco Ladisa, Michel A. Duchosal, Aimable Nahimana, Roberto M. Lemoli, Michele Cea

Blood (2023) 142 (Supplement 1): 6609.

https://doi.org/10.1182/blood-2023-189720

Published: 2023

Journal Articles

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Blood (2023) 141 (21): 2615–2628.

https://doi.org/10.1182/blood.2022019240

Published: 2023

Includes: Supplemental data

Journal Articles

The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities

Debora Soncini, Pamela Becherini, Elisa Gelli, Claudia Martinuzzi, Fabio Guolo, Antonino Neri, Antonia Cagnetta, Roberto Massimo Lemoli, Michele Cea

Blood (2022) 140 (Supplement 1): 9929.

https://doi.org/10.1182/blood-2022-169453

Published: 2022

Journal Articles

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated with Expansion and Maturation of NK Cells

Blood (2022) 140 (Supplement 1): 11549–11551.

https://doi.org/10.1182/blood-2022-169136

Published: 2022

Journal Articles

Prognostic Relevance of Minimal Residual Disease in Therapy Related and Secondary Acute Myeloid Leukemia Receiving CPX-351 or Fludarabine-Based Induction

Fabio Guolo, Paola Minetto, Carola Riva, Chiara Vernarecci, Monica Passannante, Francesca Parodi, Michela Frello, Elena Maio, Beatrice Ferro, Maria Chies, Maurizio Miglino, Elisabetta Tedone, Nicoletta Colombo, Enrico Carminati, Clara Nurra, Francesco Puglisi, Antonia Cagnetta, Michele Cea, Roberto Massimo Lemoli

Blood (2022) 140 (Supplement 1): 8930–8931.

https://doi.org/10.1182/blood-2022-169394

Published: 2022

Journal Articles

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

Elisa Gelli, Antonella Laudisi, Claudia Martinuzzi, Debora Soncini, Pamela Becherini, Fabio Guolo, Concetta Conticello, Daniele Derudas, Francesco Di Raimondo, Antonia Cagnetta, Domenico Coviello, Roberto Massimo Lemoli, Michele Cea

Blood (2022) 140 (Supplement 1): 7064–7065.

https://doi.org/10.1182/blood-2022-169263

Published: 2022

Journal Articles

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Blood (2021) 138 (Supplement 1): 1262.

https://doi.org/10.1182/blood-2021-153028

Published: 2021

Journal Articles

Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens

Fabio Guolo, Paola Minetto, Marino Clavio, Maurizio Miglino, Riccardo Marcolin, Monica Passannante, Carola Riva, Michela Frello, Chiara Vernarecci, Elisabetta Tedone, Nicoletta Colombo, Enrico Carminati, Girolamo Pugliese, Clara Nurra, Antonia Cagnetta, Michele Cea, Marco Gobbi, Roberto M. Lemoli

Blood (2021) 138 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2021-153060

Published: 2021

Journal Articles

Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial

Roberto Mina, MD, Alessandra Larocca, Paolo Corradini, Nicola Cascavilla, Anna Marina Liberati, Norbert Pescosta, Francesca Fazio, Giovannino Ciccone, Andrea Capra, Francesca Patriarca, Annalisa Bernardini, Delia Rota Scalabrini, Michele Cea, Renato Zambello, Anna Baraldi, Angelo Belotti, Mario Boccadoro, Sara Bringhen, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134671

Published: 2020

Journal Articles

Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137351

Published: 2020

NARROW

Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease

High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction

Excellent Outcome in NPM1- mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated with Expansion and Maturation of NK Cells

Prognostic Relevance of Minimal Residual Disease in Therapy Related and Secondary Acute Myeloid Leukemia Receiving CPX-351 or Fludarabine-Based Induction

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Prognostic Impact of Minimal Residual Disease Assessment in Elderly Patients with Secondary Acute Myeloid Leukemia. a Comparison between CPX-351 and Intensified Fludarabine-Based Regimens

Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial

Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only